Applied Biosystems and Asuragen Collaborate with the Critical Path Institute to Improve Drug Toxicity Screening
News Nov 07, 2008
Applied Biosystems Inc. and Asuragen, Inc. are collaborating with the Critical Path Institute’s Predictive Safety Testing Consortium to develop a predictive gene signature panel that will allow pharmaceutical companies to screen potential therapeutics for toxic effects in pre-clinical samples.
As part of the collaboration, Critical Path Institute (C-Path), Applied Biosystems, and Asuragen, Inc. will partner to develop a panel of assays with gene targets determined to be associated with carcinogenicity in laboratory rats, a common model organism for pharmaceutical testing.
The collaborators will also use the Applied Biosystems assays to determine and differentiate effects that are genotoxic from non-genotoxic modes of action to assist in risk assessment. The new biomarker panel will be based on Applied Biosystems’ TaqMan® Gene Signature Array and real-time PCR technology.
“The development of robust turnkey assays to speed development of therapeutics for patients is one of the fundamental goals of the Critical Path Initiative, for which we believe we can make a difference working with partners such as Applied Biosystems and Asuragen,” said William B. Mattes, Ph.D., director of C-Path’s Predictive Safety Testing Consortium. “We expect this collaboration will facilitate broader utility of genomic biomarkers of toxicity across the industry in order to enable the early prediction and mechanistic understanding of potential carcinogens in pre-clinical research.”
The Predictive Safety Testing Consortium (PSTC) was established by C-Path to bring together major pharmaceutical companies to work in collaboration with C-Path and in coordination with the FDA. Its objective is to enable the exchange of knowledge and resources to speed drug development and improve drug safety. The Consortium currently has 16 members. Scientists from the FDA and its European counterpart, the European Medicines Agency, as well as academic experts also participate as advisors.
Increasingly, researchers are using Applied Biosystems comprehensive line of RNA analysis tools based on gold-standard TaqMan chemistry for the development of potential biomarkers. For this project, Applied Biosystems is providing PSTC scientists with its TaqMan Gene Signature Arrays. PSTC scientists will use this collection of RNA expression assays to develop a biomarker panel for use in screening potential therapeutics for carcinogenic effects in pre-clinical samples.
“Biomarkers that allow early prediction of toxicity will enable pharmaceutical companies to make better compound selection decisions and facilitate the early initiation of risk assessment work that would otherwise delay bringing important medicines to market,” said Peter Dansky, president of Applied Biosystems’ functional analysis division. “We are committed to continue expanding our menu of TaqMan Arrays for applications requiring a robust and highly-sensitive detection system in an easy-to-use and standardized format, such as in high-throughput drug screening.”
The development of tools that improve drug toxicity screening involves the generation and analysis of vast amounts of molecular data. Asuragen is contributing crucial laboratory services, pharmacogenomic expertise, and bioinformatics capabilities for the Predictive Safety Testing Consortium project.
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE